As new CFTR modulator therapies become available to greater numbers of eligible pwCF, it is crucial to investigate potential treatment effects on not just the lungs but a wide range of systems in CF, including the GI system (6, 25). The gene discussed is CFTR; the disease is cystic fibrosis.